It addresses pulmonary microvascular cell proliferation rather than vascular tone, and it offers the potential to at least partially correct the BMPR2/TGFB signaling imbalance seen in PAH [16]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.